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Two novel calpain inhibitors (A-705239 and A-705253)
were studied in isolated perfused rabbit hearts subjected
to 60-min occlusion of the ramus interventricularis of the
left coronary artery (below the origin of the first diagonal
branch), followed by 120 min of reperfusion. The inhibi-
tors were added to the perfusion fluid in various final con-
centrations from the beginning of the experiments before
the coronary artery was blocked. Hemodynamic moni-
toring and biochemical analysis of perfusion fluid from
the coronary outflow were carried out. Myocardial infarct
size and the area at risk (transiently non-perfused myo-
cardium) were determined from left ventricular slices after
a special staining procedure with Evans blue and 2,3,5-
triphenyltetrazolium chloride. The infarcted area (dead
myocardium) was 77.9"2.3% of the area at risk in
untreated controls (ns12). The infarct size was signifi-
cantly reduced in the presence of both calpain inhibitors.
The best effect was achieved with 10-8 M A-705253
(ns8), which reduced (p-0.001) the infarcted area to
49.3"3.9% of the area at risk, corresponding to an
infarct reduction of 61.8%. No statistical difference was
observed between the experimental groups in coronary
perfusion, left ventricular pressure, and in the release of
lactate dehydrogenase and creatine kinase from heart
muscle.
Keywords: coronary perfusion; coronary occlusion;
enzyme release; infarct size; left ventricular pressure.
Introduction
Besides their physiological functions in cytoskeletal
remodeling and signal transduction, calpains (calcium-
dependent cytosolic cysteine proteases) are also impli-
cated in pathophysiological processes, especially with
disturbed calcium homeostasis (Goll et al., 2003). Thus,
calpains were found to be involved in myocardial tissue
damage resulting from ischemia and reperfusion, such as
sarcomer disorder, desmin degradation and proteolysis
of calspectin (Yoshida et al., 1995; Papp et al., 2000).
Calpain activity increases during myocardial hypoxia
(Iizuka et al., 1991), and activated calpains were localized
by specific antibodies in infarcted regions of the human
heart (Kunimatsu et al., 1999). Calpain inhibition, on the
other hand, attenuates or prevents myocardial tissue
damage and mitochondrial dysfunction by ischemia and
reperfusion (Neuhof et al., 2003). Increased calpain activ-
ity during hypoxia (Iizuka et al., 1991) can be reduced
with peptidyl aldehyde calpain inhibitor-I. Calpain inhibi-
tors were also found to be protective in prolonged hypo-
thermic cardiac preservation (Saito et al., 1999) and
against virus-induced apoptotic myocardial injury (De-
Biasi et al., 2001). So far, only a few studies are available
regarding the effect of calpain inhibition in experimental
models of myocardial infarction, in which the infarct size
could be reduced by pretreatment with the calcium-acti-
vated neutral protease inhibitor E-64c in dogs (Toda et
al., 1989) or with calpain inhibitor-I in isolated perfused
rat hearts (Iwamoto et al., 1999; Perrin et al., 2003).
Therefore, in the present study we have evaluated the
cardioprotective properties of two newly developed cal-
pain inhibitors (Lubisch et al., 2003) in isolated perfused
rabbit hearts following temporary coronary occlusion.
Results
Exclusion of experiments from statistical analysis
Four of 16 control experiments without inhibitor had to
be ended before completion because of severe arrhyth-
mias and ventricular fibrillation, and two further hearts
could not be evaluated due to imperfect staining. Of the
A-705253-treated hearts, 2 out of 10 experiments each
with 10-8, 10-9 and 10-10 M inhibitor concentrations had to
be excluded because of arrhythmias and ventricular fib-
rillation. Two poorly stained hearts were further excluded
from the 10-10 M treatment group. In the A-705239 exper-
iments 2 out of 8 hearts developed arrhythmias and ven-
tricular fibrillation and had to be ended before completion
and excluded from final statistical analysis. The high
exclusion rate due to severe arrhythmias and ventricular
fibrillation (20–25%), as usually observed in animal mod-
els of myocardial infarction (Ravn et al., 1999; Waagstein
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Figure 1 Time course of coronary perfusion of isolated perfused rabbit hearts.
The isolated hearts were subjected to transient occlusion of the ramus interventricularis of the left coronary artery for 60 min, followed
by 120 min of reperfusion. Control experiments without inhibitor are represented by a solid line and inhibitor-treated hearts by dotted
lines. Data are expressed as mean values"SEM.
et al., 1999) however, did not differ statistically between
the experimental groups, and thus did not adulterate the
results.
Coronary perfusion, systolic left ventricular pressure
and heart rate
Coronary occlusion was immediately followed by a sig-
nificant (p-0.001) reduction in coronary perfusion of
approximately 15.4%, from its baseline of 34.5"0.6 to
29.2"0.6 ml/min in all perfused hearts (ns40). With
reperfusion, coronary flow increased initially by approxi-
mately 9.1%, from 28.6"0.6 to 31.2"0.7 ml/min. After
10 min of reperfusion the flow rate continuously
decreased again to a range between 22.3 and 25.5 ml/
min. Untreated and treated hearts showed the same
behavior (Figure 1).
Similarly, the systolic left ventricular pressure dropped
significantly (p-0.01) in all perfused hearts (ns40) imme-
diately after coronary occlusion by approximately 26%,
from its baseline of 77.0"1.9 to 56.4"1.9 mmHg; how-
ever, it did not recover during reperfusion (Figure 2).
There was no statistical difference between the experi-
mental groups.
The heart rate was in the range between 190 and
165 min-1 during all experiments, except for hearts treat-
ed with 10-10 M A-705253 and 10-8 M A-705239, for which
the heart rate decreased by approximately 20 beats
min-1 up to the end of reperfusion.
Enzyme release from heart muscle and potassium
concentration
The concentrations of lactate dehydrogenase and crea-
tine kinase in the perfusate increased significantly
(p-0.001) during reperfusion in all experiments to
between 23.2 and 39.0 U/l and between 66.0 and 87.8
U/l, respectively. However, no statistical difference was
found between the different experimental groups. Potas-
sium levels in the perfusion fluid remained constant at
between 4.611"0.010 and 4.669"0.008 mM during all
experiments.
Area at risk and infarct size
The area of myocardium, the so-called area at risk, which
was temporarily excluded from perfusion, was
40.6"1.9% of the total left ventricle wall below the level
of coronary occlusion in all hearts evaluated (ns40). An
infarct size (dead tissue/necrosis) of 77.9"2.3% of the
area at risk was observed in untreated control hearts
after 120 min of reperfusion (Figure 3). In the presence
of calpain inhibitor A-705253 at a concentration of
10-8 M, the infarcted area was significantly (p-0.001)
reduced to 49.3"3.9% of the area at risk, corresponding
to an infarct reduction of 61.8%. This protective effect
decreased with decreasing inhibitor concentrations: to
58.1"2.2% with 10-9 M and to 62.1"7.3% of area at risk
with 10-10 M. Calpain inhibitor A-705239 at 10-8 M had the
weakest cardioprotective effect, with a reduction of the
infarcted area to only 65.8% of the area at risk.
Discussion
This study demonstrates for the first time the cardiopro-
tective effect of two newly developed calpain inhibitors
(A-705239 and A-705253) in a model of myocardial
infarction in isolated perfused rabbit hearts. Both inhibi-
tors significantly reduced the infarct size when adminis-
tered prior to coronary occlusion and reperfusion.
The remarkably low inhibitor concentration of 10-8 M
used in these experiments, which was found to be the
most effective in a recent study on global myocardial
ischemia (Neuhof et al., 2003), is due to its excellent
water solubility and good tissue availability (Lubisch et
al., 2003) which results in a 16-fold inhibitor accumulation
in the heart muscle.
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Figure 2 Time course of systolic left-ventricular pressure of isolated perfused rabbit hearts.
Hearts were subjected to transient occlusion of the ramus interventricularis of the left coronary artery for 60 min, which was followed
by 120 min of reperfusion. Control experiments without inhibitor are represented by a solid line and inhibitor-treated hearts by dotted
lines. Data are expressed as mean values"SEM.
Figure 3 Development of myocardial infarction in isolated per-
fused rabbit hearts.
Experimental occlusion of the ramus interventricularis of the left
coronary artery for 60 min was followed by 120 min of reperfu-
sion. Infarct size is expressed in percentage of the area at risk
(the transiently non-perfused myocardium). Control experiments
without inhibitor are represented by a dark-colored column and
inhibitor-treated hearts by light-colored columns. Data are pre-
sented as mean values"SD. Infarct size is significantly reduced
by calpain inhibition in all treated hearts compared to untreated
controls.
Increased attention has been focused over the past
two decades on calpains, besides cardiomyocyte con-
tracture, reactive oxygen species and lysosomal prote-
ases, as leading players in lethal myocardial cell injury
during ischemia and reperfusion. Cytosolic Ca2qoverload
during ischemia and reperfusion (Kihara et al., 1989; Mar-
ban et al., 1990) is considered to be mainly responsible
for the activation of calcium-dependent calpains, local-
ized primarily in the Z-disk/I-band region (Yoshimura et
al., 1986; Kumamoto et al., 1992), and the subsequent
breakdown of myocardial proteins. Thus, the calpain-
dependent degradation of desmin, calspectrin (Yoshida
et al., 1995; Papp et al., 2000), troponin I and T, and
sarcoplasmic reticulum proteins (Singh et al., 2004), cor-
responding to the myofilament disintegration observed
by electron microscopy (Gao et al., 1997; Goette et al.,
2002), has been reported in ischemia-reperfusion mod-
els. Furthermore, calpain activation in ischemia and
reperfusion is accompanied by the downregulation of
calpastatin, its natural inhibitor (Sorimachi et al., 1997;
Enns et al., 2002). Besides direct myofilament disintegra-
tion, mitochondrial dysfunction is also considered to con-
tribute essentially to cardiac dysfunction and myocyte
injury during ischemia and reperfusion (Lesnefsky et al.,
2001). This assumption is supported by observations that
calpain inhibition (Neuhof et al., 2003) or the prevention
of calpain activation by Naq/Hq exchange inhibition
(Chen et al., 2002) reduces mitochondrial dysfunction
during myocardial ischemia and reperfusion.
Our results showing a decrease in infarct size by cal-
pain inhibition in rabbits are in accordance with experi-
mental findings in rats (Iwamoto et al., 1999; Perrin et al.,
2003) and dogs (Toda et al., 1989). No reduction in the
release of lactate dehydrogenase and creatine kinase by
calpain inhibition, as observed after global myocardial
ischemia (Chen et al., 2002; Neuhof et al., 2003; Liu and
Schellmann, 2003), was found in our study with transient
local ischemia. This may be due to an enzyme loss from
small affected tissue volumes with insufficient concentra-
tion for detection. Differences in coronary flow between
treated and untreated hearts are not expected, because
infarcted areas are reperfused as well. The slowly
decreasing coronary flow up to the end of the experiment
can be related to increasing vascular resistance (by
endothelial swelling), as also observed in normal per-
fused hearts without ischemia. Inhibitor-treated hearts
with significantly reduced infarct size did not show better
myocardial function (ventricular pressure performance)
than untreated controls during 120 min of reperfusion.
This behavior is clarified by observations that the salvage
of myocardium from necrosis after local ischemia by
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reperfusion has little instant effect on systolic myocardial
performance, as its functional recovery takes up to
4 weeks (Theroux et al., 1976; Lavallee et al., 1983; Ellis
et al., 1985). To evaluate not only the salvage from necro-
sis, but also the return of function, longer experiments
have to be performed in intact animals. In contrast to the
infarct model, in which the time of transient local ische-
mia is chosen to be long enough to develop necrosis, in
models of global ischemia the duration of perfusion ces-
sation is restricted to enable at least a speedy recovery
with reperfusion.
As the calpain inhibitors used in our study also inhibit
the lysosomal cysteine proteases cathepsin B and L, it
should be discussed whether inhibition of both proteases
could account for the cardioprotective effect. So far, poor
information is available for both cathepsins in the heart.
Thus, activation of cathepsin L was found in the intraly-
sosomal compartment of cardiomyocytes during coro-
nary aortal bypass (Turski and Zaslonka, 2000). The
increase in functional recovery and the decrease in pro-
tein degradation, total activity of cathepsin B and L, and
in cathepsin B leakage by cysteine proteinase inhibitors
in experimental models of myocardial ischemia and
infarction (Tsuchida et al., 1986; Shibata et al., 1992),
however, cannot be related to both proteinases, as these
inhibitors could also inhibit calpains. Recently we
showed (unpublished data) that both calpain inhibitor A-
705253 and the Naq/Hq exchange inhibitor Cariporide
reduced infarct size by the same degree, without an addi-
tive effect when they were combined. These findings
suggest that cardioprotection in our study is due to cal-
pain inhibition, because cathepsin B and L are not cal-
cium-activated proteases and their activity would not be
inhibited by an Naq/Hq exchange inhibitor.
The novel calpain inhibitors A-705239 and A-705253
showed excellent protection against myocardial infarc-
tion after transient local coronary occlusion and reper-
fusion when administered prior to the onset of ischemia.
These findings may suggest prophylactic calpain inhibi-
tion in clinical situations of coronary surgery and coro-
nary angioplasty, which are often threatened by acute
myocardial infarction. Its protective efficacy when admin-
istered in later stages of coronary occlusion has yet to
be evaluated in further studies.
Materials and methods
This study was approved by the Institutional Animal Care and
Use Committee of the Justus-Liebig-University of Giessen and
was performed in accordance with the guidelines of the National
Institute of Health (USA).
Reagents and materials
Calpain inhibitor A-705239 and A-705253 (Abbott GmbH & Co
KG, Ludwigshafen, Germany) are representatives of a novel
class of non-peptide calpain inhibitors, as described by Lubisch
et al. (2003). They are benzoylalanine-derived ketoamides car-
rying vinylbenzyl amino residues in the P2/P3 region and inhibit
calpain in nanomolar concentrations. A-705239 inhibits calpain-
I with a Ki of 13.3"1.5 nM, and A-705253 with a Ki of 27"2.5 nM
for the enzyme-inhibitor complex. Cathepsin B and L are inhib-
ited by A-705239 with a Ki of 27"6 and 22"3 nM, respectively,
and are inhibited by A-705253 with a Ki of 62"9 and 149"15 nM,
respectively. No inhibition is detected for yeast proteasome,
papain and human ICE/caspase1 at concentrations above
10 mM.
Poly(O-2-hydroxyethyl)-starch (HAES-steril 10%) was
obtained from Fresenius (Bad Homburg, Germany), and Custa-
diol from Dr. F. Ko¨hler Chemie GmbH (Alsbach-Ha¨nlein, Ger-
many). Na-pyruvate and 2,3,5-triphenyltetrazolium chloride were
purchased from Sigma-Aldrich (Deisenhofen, Germany), and
Evans blue from Merck KGaA (Darmstadt, Germany).
Isolated heart preparation
Half-breed rabbits of either sex weighing between 2.5 and 3.2 kg
were anesthetized with pentobarbital sodium (60–80 mg/kg) and
anticoagulated with heparin sodium (1000 IU/kg) injected into an
ear vein. A tracheotomy was performed, and the rabbits were
mechanically ventilated with room air by means of a Starling
pump (B. Braun, Melsungen, Germany). The thorax was opened
via the diaphragma, followed by a median sternotomy. The aorta
was cannulated retrogradely and cardioplegia was induced by
injection of 25–30 ml of ice-cold (48C) Bretschneider solution
(Custadiol). The hearts were excised, mounted onto a modified
Langendorff perfusion system and excess tissue was removed.
A latex balloon (1.3-ml capacity) for pressure monitoring was
inserted into the left ventricle and connected to a second extra-
corporeal circuit according to the ‘working’ heart model, as
described by Bardenheuer and Schrader (1983). Left end-dia-
stolic influx pressure (preload) was set hydrostatically to
7 mmHg and ‘aortic’ pressure (afterload) to 50 mmHg by means
of a water-filled reservoir and the height of the outflow tube,
respectively. After a cardioplegic arrest of 3–4 min, the hearts
were perfused retrogradely with a constant hydrostatic pressure
of 70 mmHg with oxygenated Krebs-Henseleit-HAES buffer at
378C, which was filtered through a 0.2-mm Pall filter (Pall Bio-
medical Inc, Fajardo, Puerto Rico). The buffer was bubbled with
a mixture of 95% O2 and 5% CO2 resulting in PO2 of
)400 mmHg in the perfusate and)200 mmHg in the coronary
effluent, and the pH was maintained between 7.35 and 7.45 by
increasing or decreasing the CO2 admixture. During experi-
ments, the spontaneously beating hearts were submerged in a
container (25-ml capacity) at 378C filled with the coronary efflu-
ent to prevent exsiccation. Coronary perfusion pressure and cor-
onary flow were measured continuously with a pressure
transducer (Combitrans, B. Braun) and electromagnetic flow
probe (Empo/Gould, Oxnard, USA), respectively, in the perfusion
line. Left ventricular pressure (LVSP) and end-diastolic pressure
(LVEP) were measured with another pressure transducer con-
nected to a balloon inserted into the cavity of the left ventricle.
Isovolumetric left ventricular pressure was measured intermit-
tently by clamping off the connections to the inflow reservoir and
the outflow tube. A bipolar electrocardiogram was conducted
from apex versus heart base. All these parameters were moni-
tored continuously and recorded on a multichannel recorder.
Perfusate
For perfusion, a modified Krebs-Henseleit buffer solution (KHHB)
with Na-pyruvate (0.5 g/l) was prepared, and hydroxyethyl starch
(HAES-steril 10%) was added to keep colloid oncotic pressure
between 23 and 25 mmHg, yielding the following final concen-
trations: starch, 50 g/l; Naq, 138 mM; Kq, 4.5 mM; Mg2q,
1.33 mM; Cly, 135 mM; Ca2q, 2.38 mM; glucose, 12 mM; Na-
pyruvate, 4.5 mM; and HCO3y, 12 mM. Osmolality was approx-
imately 330 mosmol/kg. The pH of the perfusate was adjusted
to 7.4 with 1 M NaHCO3 before use. Oncotic pressure and osmo-
lality were controlled with an Onkometer (BMT 921, Dr. Karl Tho-
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mae, Biberach, Germany) and a Mikro-Osmometer (Roebling
Messtechnik, Berlin, Germany).
Experimental protocol
Perfused hearts were stabilized for 20 min. After this steady-
state period, the ramus interventricularis of the left coronary
artery was blocked by means of a tourniquet just below the ori-
gin of the first diagonal branch for 60 min. Hearts selected for
the study were those that developed a constant systolic left ven-
tricular pressure of more than 60 mmHg during the steady-state
period. After 60 min of occlusion the tourniquet was reopened
and the coronary reperfused for 120 min.
In 10 perfused hearts each, calpain inhibitor A-705253 was
added to the perfusate from the beginning of perfusion at final
concentrations of 10-8, 10-9, and 10-10 M, respectively. In a further
6 experiments inhibitor A-705239 was used at a final concentra-
tion of 10-8 M. Sixteen hearts were treated without inhibitor as
controls.
Measurements
Isovolumetric left ventricular pressure amplitude and heart rate
were determined from pressure records and electrocardiograms,
respectively. Coronary flow was monitored continuously with an
electromagnetic flow transducer. Samples of coronary effluent
were collected intermittently for control of pH, PO2, and PCO2,
and for determination of creatine kinase and lactate dehydro-
genase activity using kits from Boehringer-Mannheim (Mann-
heim, Germany).
Determination of area at risk and infarct size
At the end of each experiment perfusion was stopped and the
ramus interventricularis of the left coronary artery was closed
again using the tourniquet. Five ml of Evans blue (5%) was
injected via the perfusion catheter into the coronary circulation
to stain the non-ischemic zone blue and to demarcate the area
at risk. The atria, right ventricle, and great vessels were removed
and the left ventricle was cut in 7–8 slices of approximately
3 mm in thickness, which were then incubated in 2,3,5-triphe-
nyltetrazolium chloride (1%) for 15 min at a temperature of 378C.
By this procedure, normal perfused myocardium was stained
blue and the viable tissue within the area at risk was stained red,
whereas the infarcted dead myocardium remained unstained.
The stained slices were photographed on both sides by means
of a digital camera (Coolpix 950, Nikon Corp, Tokyo, Japan). The
computer programs Paint Shop Pro6 (Jasc Software Inc, Eden
Prairie, MN, USA) and Image J (NIH, USA) were used for color
discrimination and planimetric evaluation of normal perfused
myocardium, the area at risk, and infarct size. Both sides of each
left ventricle slice were evaluated and the areas corresponding
to different colors were added up. Infarct size (dead myocardi-
um) was expressed as percentage of area at risk (the temporarily
non-perfused myocardium due to the 60 min of coronary
occlusion).
Statistics
The data were analyzed by means of the Statgraphics-Plus sta-
tistical analysis package from Statistical Graphics Corporation
(Rockville, MD, USA). Intergroup analysis was performed by
analysis of variance. Fisher’s LSD test was used for multiple
group comparison. Data are presented as mean"standard error
of the mean. A significant difference was defined as p-0.05.
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